Lonza CEO says reviewing biosimilar venture with Teva
ZURICH (Reuters) - Swiss specialty chemicals and life sciences group Lonza is reviewing whether it is still worth investing in its joint venture with ...
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/HnT1Xu5NkSQ/story01.htm
No comments:
Post a Comment